Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases.
Katagiri D, Asai Y, Ohmagari N, Ishikane M, Hikida S, Iwamoto N, Nagashima M, Suzuki M, Takano H, Takasaki J, Hojo M, Sugiyama H, Tokunaga K, Miyashita Y, Omata M, Ohata K, Bliden KP, Tantry US, Dahlen JR, Sugaya T, Gurbel PA, Noiri E. Katagiri D, et al. Among authors: sugiyama h. Crit Care Explor. 2023 Mar 9;5(3):e0873. doi: 10.1097/CCE.0000000000000873. eCollection 2023 Mar. Crit Care Explor. 2023. PMID: 36910457 Free PMC article.
Inhaled ciclesonide does not affect production of antibodies or elimination of virus in patients with COVID-19: Subanalysis of a multicenter, open-label randomized trial.
Suzuki M, Matsunaga A, Miyoshi-Akiyama T, Terada-Hirashima J, Sadamasu K, Nagashima M, Takasaki J, Izumi S, Hojo M, Ishizaka Y, Sugiyama H. Suzuki M, et al. Among authors: sugiyama h. Drug Discov Ther. 2023 Nov 18;17(5):304-311. doi: 10.5582/ddt.2023.01078. Epub 2023 Oct 30. Drug Discov Ther. 2023. PMID: 37899206 Free article. Clinical Trial.
Diagnostic accuracy of direct reverse transcription-polymerase chain reaction using guanidine-based and guanidine-free inactivators for SARS-CoV-2 detection in saliva samples.
Katsuno T, Kimura M, Terada-Hirashima J, Kazuyama Y, Ikeda M, Moriya A, Kurokawa M, Motohashi A, Isaka E, Morishita M, Kawajiri K, Hakkaku K, Saito S, Terayama Y, Sugiura Y, Yamaguchi Y, Takumida H, Watanabe H, Morita C, Tsukada A, Kusaba Y, Tsujimoto Y, Ishida A, Sakamoto K, Hashimoto M, Suzuki M, Takasaki J, Izumi S, Hojo M, Sugiyama H, Sugiura W. Katsuno T, et al. Among authors: sugiyama h. J Virol Methods. 2024 May;326:114909. doi: 10.1016/j.jviromet.2024.114909. Epub 2024 Mar 5. J Virol Methods. 2024. PMID: 38452822
Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine.
Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Horii K, Okudera K, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: sugiyama h. Clin Microbiol Infect. 2023 Sep;29(9):1201.e1-1201.e5. doi: 10.1016/j.cmi.2023.05.020. Epub 2023 May 24. Clin Microbiol Infect. 2023. PMID: 37236545 Free PMC article.
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Takeuchi JS, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: sugiyama h. Int J Infect Dis. 2023 Mar;128:347-354. doi: 10.1016/j.ijid.2023.01.023. Epub 2023 Jan 22. Int J Infect Dis. 2023. PMID: 36693493 Free PMC article.
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Nemoto T, Takeuchi JS, Li Y, Konishi M, Tsuchiya K, Gatanaga H, Oka S, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: sugiyama h. J Infect Dis. 2023 Dec 20;228(12):1652-1661. doi: 10.1093/infdis/jiad317. J Infect Dis. 2023. PMID: 37756608
2,703 results